NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Diagnostics & Research · USD

Danaher Corporation (DHR) Stock Analysis

Danaher Corporation (DHR) is a Diagnostics & Research stock listed on NYSE and quoted in US Dollar.

DHR

$207.66

−$3.37 (−1.60%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare DHR with… →

DHR Key Statistics

As of Sep 4, 2026
Trading
Open
$207.19
Previous Close
$211.03
Day's Range
205.23–208.70
52-Week Range
160.93–242.80
Volume
2.90M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.81
Valuation
Market Cap
$145.98B
P/E Ratio
37.02
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
22.34
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.26
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
5.81
EPS (ttm)Profit attributable to each share over the last twelve months.
5.61
Financials (FY)
Revenue (FY)
$24.57B+2.90%
Net Income (FY)
$3.61B−7.31%
Profit marginThe share of revenue left as profit after all costs and taxes.
15.95%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
702.99M
1-Year Return
+5.11%
Dividend and dates
Dividend
$1.60+0.76%
Ex-Dividend Date
June 26, 2026
Earnings Date
October 20, 2026
Avg Volume
4.67M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

DHR Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−8.91%
2025+0.35%
2024−0.35%
2023−1.24%
2022−19.02%
2021+48.57%
2020+45.34%
2019+49.55%
2018+11.80%
2017+20.01%
2016 (partial year)−3.93%

As of September 4, 2026.

DHR Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$24.57B$3.61B14.7%
2024$23.88B$3.90B16.3%
2023$23.89B$4.76B19.9%
2022$26.64B$7.21B27.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$24.57B$14.52B$4.69B$3.61B14.7%
2024$23.88B$14.21B$4.86B$3.90B16.3%
2023$23.89B$14.03B$5.20B$4.76B19.9%
2022$26.64B$16.19B$7.54B$7.21B27.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

DHR Dividend History

$1.28+18.5% vs 2024

Dividends per share, 2025 · 4 payments

YearDividends per sharePaymentsChange
2026*$0.802—
2025$1.284+18.5%
2024$1.084+9.2%
2023$0.994+11.5%
YearDividends per sharePaymentsChange
2026 (partial year)$0.802—
2025$1.284+18.5%
2024$1.084+9.2%
2023$0.994+11.5%
2022$0.894+19.0%
2021$0.744+16.7%
2020$0.644+5.9%
2019$0.604+6.2%
2018$0.574+14.3%
2017$0.504+124.0%
2016$0.222—

Most recent payment: $0.40 per share, ex-dividend June 26, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

DHR Valuation vs Diagnostics & Research Median

Median of 49 stocks
MetricDHRDiagnostics & Research medianvs median
P/E37.0233.0812% above
P/S ratio5.814.9917% above
Profit margin15.95%0.00%15.9 pts above

Medians across 49 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Danaher Corporation (DHR) is capitalised at $145.98B on the latest close. The company sits in the Healthcare sector, in the Diagnostics & Research industry. Headcount on file is 58,000.

The most recent close on file for DHR is $207.66, dated September 4, 2026. That is −$3.37 (−1.60%) against the previous close. Over the past 52 weeks the price has ranged from $160.93 to $242.80. The latest close sits 29.04% above that 52-week low.

Financial Health

In fiscal 2025, Danaher Corporation reported revenue of $24.57B. That is +2.90% against the prior fiscal year, when revenue was $23.88B. The same year closed with net income of $3.61B. That is −7.31% against the prior fiscal year. Profit margin runs at 15.95%. That is 15.9 percentage points above the Diagnostics & Research median of 0%. Earnings per share on a trailing basis come to 5.61.

Across the 4 fiscal years on file, revenue moves from $26.64B in 2022 to $24.57B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 37.02. That is 11.91% above the Diagnostics & Research median of 33.08. The forward P/E on file is 22.34. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.26. Measured against sales, the shares trade at 5.81 times revenue. On price-to-sales that is 16.51% above the Diagnostics & Research median of 4.99. The medians here are taken across 49 Diagnostics & Research companies that report the metric.

Beta against the wider market is reported at 0.81. Daily returns over the trailing 10 years annualize to a volatility of 26.16%. Over the trailing twelve months the price has returned +5.11%. Measured over 10 years, that is +11.75% a year compounded.

Growth & Income

The trailing dividend yield is 0.76%. The indicated annual rate is $1.60 a share. The ex-dividend date on file is June 26, 2026. Dividends are recorded for 11 calendar years; 2026 shows 2 payments totalling $0.80 a share. The year before, 2025, totalled $1.28 a share.

2026 is still running; the price is −8.91% year to date. The strongest complete calendar year on file is 2019 at +49.55%; the weakest is 2022 at −19.02%. Of the 9 complete calendar years on file, 6 finished higher.

Peer Comparison

Danaher Corporation (DHR) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Danaher Corporation DHR $145.98B 37.0
Thermo Fisher Scientific Inc. TMO $226.94B 33.0
Natera, Inc. NTRA $47.31B —
IQVIA Holdings Inc. IQV $44.07B 33.8

The Diagnostics & Research industry average P/E ratio is 33.1x. Danaher Corporation trades at a P/E of 37.0.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$226.94B

 NTRA

Natera, Inc.

$47.31B

 IQV

IQVIA Holdings Inc.

$44.07B

 A

Agilent Technologies, Inc.

$42.54B

 IDXX

IDEXX Laboratories, Inc.

$42.18B

 WAT

Waters Corporation

$40.20B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Danaher Corporation

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

Visit website →